{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:43:56Z","timestamp":1767998636795,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009960","name":"Pirkanmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["150617"],"award-info":[{"award-number":["150617"]}],"id":[{"id":"10.13039\/501100009960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.euf.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T21:41:30Z","timestamp":1490391690000},"page":"851-857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-9590","authenticated-orcid":false,"given":"Teemu Johannes","family":"Murtola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arla M.","family":"Vettenranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Taari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf-H\u00e5kan","family":"Stenman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2017.03.005_bib0005","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-Cancer mortality at 11 years of follow up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.03.005_bib0010","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-13-1573","article-title":"NSAIDs inhibit tumorigenesis, but how?","volume":"20","author":"Gurpinar","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2017.03.005_bib0015","first-page":"12","article-title":"Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis","volume":"28","author":"Liu","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.euf.2017.03.005_bib0020","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ejca.2012.09.030","article-title":"Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level","volume":"49","author":"Veitonm\u00e4ki","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2017.03.005_bib0025","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/ijc.25465","article-title":"Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case\u2013control study (the ProtecT study)","volume":"128","author":"Murad","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2017.03.005_bib0030","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2009.27.9406","article-title":"Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey","volume":"28","author":"Chang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.03.005_bib0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0022-5347(05)65186-5","article-title":"Treatment of chronic prostatitis lowers serum prostate specific antigen","volume":"167","author":"Bozeman","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.03.005_bib0040","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/cncr.23806","article-title":"Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001\u20132002 National Health and Nutrition Examination Survey","volume":"113","author":"Singer","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2017.03.005_bib0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5301\/RU.2012.9364","article-title":"Impacts of antibiotic and anti-inflammatory therapy on serum prostate specific antigen in asymptomatic men: our experience","volume":"79","author":"Del Rosso","year":"2012","journal-title":"Urologia (Treviso)"},{"key":"10.1016\/j.euf.2017.03.005_bib0050","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djt038","article-title":"Prostate cancer mortality in the Finnish randomized screening trial","volume":"105","author":"Kilpel\u00e4inen","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2017.03.005_bib0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2017.03.005_bib0060","doi-asserted-by":"crossref","unstructured":"McDonald AC, Vira MA, Vidal AC, et al. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease\u2014the 2001\u20132008 National Health and Nutrition Examination Survey. Prostate 1014;74:561\u20137.","DOI":"10.1002\/pros.22782"},{"key":"10.1016\/j.euf.2017.03.005_bib0065","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bju.12153","article-title":"Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial","volume":"112","author":"Yli-Hemminki","year":"2013","journal-title":"BJU Int"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456917300731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456917300731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:47:12Z","timestamp":1762498032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456917300731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S2405456917300731"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2017.03.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}